British Patient Capital operates a £375m programme called Future Fund: Breakthrough, co-investing with private sector investors in R&D-intensive UK companies.
Ian brings investment and fund management experience from roles at British Business Bank and British Patient Capital, where he currently serves as Managing Partner of the British Growth Partnership.
Tom brings investment and operating experience from roles at 24Haymarket, British Patient Capital, and Foresight Group. He previously co-founded Puridify.
General Catalyst led the financing alongside a syndicate of new and existing investors to support the developer of antibody-based therapeutics.
"KnotBodies represent a potential breakthrough biologic drug modality, delivering greater potency, selectivity, and durability. We believe they will provide transformational new therapeutic options for ion channel- and GPCR-driven diseases across a wide range of therapeutic areas with a remaining high unmet medical need. The calibre of our international investor syndicate validates our approach, and I would like to welcome our new investors to Maxion and thank our existing investors for their continued support."
The financing values the decision intelligence provider at $2.6bn and was led by Teachers Venture Growth.
"Businesses today need to build trusted data foundations to enable AI-enhanced decision making, to drive real world impact. Quantexa is revolutionising how they do this. At TVG, we invest in high-growth, game-changing companies, led by visionary leaders, making a global difference. Quantexa’s impressive track record, expanding customer base, and bold approach to data and AI innovation make it a natural fit for our portfolio. We’re excited to support Vishal, and his world-class team scale the company internationally, as they continue helping industry-leading organisations embrace AI-driven decision-making with confidence."
— Avid Larizadeh Duggan, Senior Managing Director and Head of TVG in EMEA
The Series C round was led by a strategic investor and backed by existing supporters to drive international expansion.
"We are delighted to continue backing the ambitious CGD team in bringing groundbreaking GaN technologies to market. As we strive towards a low-carbon future, CGD’s products can deliver higher performance while enabling up to 50% energy savings across multiple growing sectors such as automotive, renewable energy, and data centres. We look forward to seeing the impact that CGD can make in enabling greener power electronics"
The Series C financing was led by Elevage Medical Technologies with backing from Patient Square Capital and other investors.
"This significant investment demonstrates continued confidence in our team, our eProtein Discovery system, and our potential to revolutionize the way proteins are made. This funding will accelerate our mission to provide ready-to-use benchtop protein screening and making tools to empower protein scientists around the world. We are excited to enhance our support for our customers, enabling them to make proteins for drug discovery more efficiently and effectively for many years to come."
The financing round was led by Sofinnova Partners and will fund upcoming clinical trials for kidney disease treatments.
"Our investment into Purespring Therapeutics fits perfectly into our strategy to support the UK’s life sciences and is the type of UK growth company which could benefit further by unlocking the potential of institutional investment. We need to support companies like Purespring as they go through development and trials before coming to market.Providing that capital simultaneously stimulates growth and helps to solve pressing medical challenges that will deliver long-term outcomes for generations to come."
— Ian Connatty, Managing Director, Direct & Co-Investment
